Magdeburg researchers discover a new mechanism of cancer immune defense
Modern immunotherapies boost the body's own defenses against cancer. They activate killer T cells of the immune system that can specifically recognize and destroy cancer cells. In many patients, however, cancer cells adapt and become invisible to killer T cells so that the treatment is no longer effective. An interdisciplinary team of researchers from Magdeburg has now discovered a new mechanism that enables the immune system to also eliminate such invisible cancer cells. (Source: World Pharma News)
Source: World Pharma News - June 23, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Roundup: South Korean AI software for sepsis detection gets US FDA nod and more briefs
Also, South Korean researchers have built an AI model for predicting the side effects of immunotherapy on a patient. (Source: mobihealthnews)
Source: mobihealthnews - June 23, 2023 Category: Information Technology Source Type: news
Study hints at how cancer immunotherapy can be safer
New research can help scientists predict, treat, or even prevent side effects of immunotherapies that rely on disabling protective proteins in healthy tissues. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 21, 2023 Category: Universities & Medical Training Source Type: news
cAMPing up cancer immunotherapy | Science Signaling
Adrenergic receptor stimulation improves cancer immunotherapy in a range of immune-competent tumor models. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 20, 2023 Category: Science Source Type: news
Navidea secures $7.5M from Cardinal Health
Immunodiagnostics and immunotherapy drug developer Navidea Biopharmaceutical...Read more on AuntMinnie.comRelated Reading:
NYSE American notifies Navidea of listing noncompliance
Navidea to sell $8M milestone payment
Navidea posts deep Q3 revenue decreases
FDA clears Cardinal's Lymphoseek for pediatric use
Cardinal Health joins SNMMI's Value Initiative (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 19, 2023 Category: Radiology Source Type: news
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two clinical stage assets to Coherus' I-O…#chrs #surfaceoncologyinc #surface #dennylanfear #cimerliand #novartisag #gskplc #pipeline #udenyca #cimerli (Source: Reuters: Health)
Source: Reuters: Health - June 16, 2023 Category: Consumer Health News Source Type: news
Managing Immunotherapy Side Effects in MBC Managing Immunotherapy Side Effects in MBC
Drs Fatima Cardoso, Hope Rugo, Rebecca Dent, and Zoe Quandt discuss a multidisciplinary approach in managing immunotherapy side effects to optimize patient care in metastatic breast cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
FDA approves Roche ’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed period of time,Columvi provides patients with a treatment end date and potential time off treatmentColumvi is part of Roche ' s industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approvedLunsumioto treat follicular lymphomaBasel, 16 June 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Source: Roche Investor Update - June 16, 2023 Category: Pharmaceuticals Source Type: news
Society for Immunotherapy of Cancer Publishes Clinical Practice...
The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer...(PRWeb June 12, 2023)Read the full story at https://www.prweb.com/releases/society_for_immunotherapy_of_cancer_publishes_clinical_practice_guideline_on_immunotherapy_for_the_treatment_of_gastrointestinal_cancer/prweb19386910.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 12, 2023 Category: Pharmaceuticals Source Type: news
2 Years of Immunotherapy for Advanced Lung Cancer Might Be Enough: Study
FRIDAY, June 9, 2023 -- For patients battling late-stage lung cancer, prospects for survival have improved significantly since the advent of medications known as immune checkpoint inhibitors.
But exactly how long patients with advanced non-small... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 9, 2023 Category: General Medicine Source Type: news
Episode 3: Immunotherapy in Advanced and Metastatic Breast Cancer Episode 3: Immunotherapy in Advanced and Metastatic Breast Cancer
Drs Banu Arun and Kevin Kalinsky discuss immunotherapy in the treatment of advanced and metastatic breast cancer, including recent studies, side effects, access to treatment, and disparities in care.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years
(MedPage Today) -- CHICAGO -- Patients with advanced non-small cell lung cancer (NSCLC) who are progression-free may discontinue treatment with frontline immunotherapy after 2 years without compromising overall survival (OS), a retrospective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2023 Category: Hematology Source Type: news
Safe to Stop Immunotherapy at 2 Years in Stable Lung Cancer Safe to Stop Immunotherapy at 2 Years in Stable Lung Cancer
A large review has found no difference in overall survival with fixed-duration vs ongoing ICI treatment in progression-free non –small cell lung cancer.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 6, 2023 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
TUESDAY, June 6, 2023 -- For patients with advanced non-small cell lung cancer (NSCLC), indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for two years, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2023 Category: Pharmaceuticals Source Type: news
Opdivo Could Boost Outcomes for People Battling Hodgkin Lymphoma
TUESDAY, July 6, 2023 -- The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard care is, new clinical trial... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 6, 2023 Category: General Medicine Source Type: news
